SpectraCell launches Baseline Nexus longevity and risk test
SpectraCell Laboratories has launched Baseline Nexus, a comprehensive health assessment test that evaluates nutrition, cardiovascular risk, genetics, and biological aging. This innovative test distinguishes itself by measuring intracellular metabolism through metabolically active peripheral lymphocytes, rather than relying solely on circulating blood analytes. By assessing DNA synthesis in a serum-free culture medium, Baseline Nexus aims to identify functional intracellular defects that may impair immune responses and overall cellular health.
The implications for the longevity and healthspan field are significant. By providing detailed insights into micronutrient deficiencies, lipoprotein profiles, telomere length, and MTHFR genotyping, the test equips clinicians and individuals with actionable data to inform interventions. This aligns with a growing trend in personalized health strategies that prioritize early risk detection and tailored therapeutic approaches.
For professionals in aging biology and healthspan research, Baseline Nexus represents a valuable tool for enhancing patient care and advancing our understanding of the biological underpinnings of longevity.